

In the Claims

Claims 1-46 (Canceled).

Claim 47 (Previously Presented): A method for stimulation of cytotoxicity by NK cells, comprising:

contacting said NK cells with an amount of antibody effective to stimulate the activity of said NK cells, said antibody specifically binding to a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

Claims 48-63 (Canceled).

Claim 64 (Previously Presented): The method according to claim 47, wherein said antibody is a polyclonal antibody.

Claim 65 (Previously Presented): The method according to claim 47, wherein said antibody is a monoclonal antibody.

Claim 66 (Previously Presented): The method according to claim 47, wherein said antibody is a humanized mouse monoclonal antibody.

Claim 67 (Previously Presented): The method according to claim 47, wherein said antibody is an antibody of human origin.

Claim 68 (Previously Presented): The method according to claim 65, wherein said monoclonal antibody is produced by the hybridoma having CNCM Registration Number I-2576.

Claims 69-73 (Canceled).

J:\INN\103TD1\response-AF.doc/DNB:ssa

Claim 74 (Currently Amended): A method for stimulation of cytotoxicity by NK cells comprising contacting said NK cells with an amount of antibody effective to stimulate the activity of said NK cells, said antibody being produced by the hybridoma having CNCM Registration Number I2576 and specifically binding to a polypeptide comprising the amino acid sequence of: SEQ ID NO: 4 or SEQ ID NO: 7.

Claims 75-79 (Canceled).

Claim 80 (Previously Presented): The method according to claim 74, wherein said antibody specifically binds to a polypeptide comprising SEQ ID NO: 4.

Claim 81 (Previously Presented): The method according to claim 74, wherein said antibody specifically binds to a polypeptide comprising SEQ ID NO: 7.

Claim 82 (Currently Amended): ~~The method according to claim 74~~ A method for stimulation of cytotoxicity by NK cells comprising contacting said NK cells with an amount of antibody effective to stimulate the activity of said NK cells, wherein said antibody specifically binds to a polypeptide consisting of SEQ ID NO: 4.

Claim 83 (Currently Amended): ~~The method according to claim 74~~ A method for stimulation of cytotoxicity by NK cells comprising contacting said NK cells with an amount of antibody effective to stimulate the activity of said NK cells, wherein said antibody specifically binds to a polypeptide consisting of SEQ ID NO: 7.

Claim 84 (Previously Presented): A method for stimulation of cytotoxicity by NK cells comprising contacting said NK cells with an amount of antibody having the binding specificity of the antibody produced by the hybridoma having CNCM Registration Number I-2576, said antibody having the ability to stimulate the cytotoxicity of said NK cells.

Claim 85 (Currently Amended): A method of binding NK cells to antibody comprising contacting said NK cells with ~~an antibody~~ a monoclonal antibody produced by hybridoma CNCM Registration Number I-2576 or an immunoreactive fragment thereof, that specifically binds to the NKp30 polypeptide (SEQ ID NO: 2) or an immunogenic fragment thereof.

Claims 86-90 (Canceled).

Claim 91 (Previously Presented): The method according to claim 85, wherein said antibody or immunoreactive fragment thereof is coupled to a label.

Claim 92 (Previously Presented): The method according to claim 91, wherein said label is a fluorescent label.

Claim 93 (Previously Presented): The method according to claim 92, wherein said antibody or immunoreactive fragment thereof is attached to a solid support.

Claim 94 (Canceled).

Claim 95 (Currently Amended): The method according to claim 85, wherein said NK cells are contacted with immunoreactive fragment of ~~an antibody that specifically binds to the NKp30 polypeptide (SEQ ID NO: 2) or an immunoreactive fragment thereof~~ a monoclonal antibody produced by CNCM Registration Number I-2576.

Claim 96 (Canceled).